c-Met/HGFR
HGF is a multifunctional growth factor. It is produced as a single-chain inactive precursor protein. Mature active HGF is a heterodimer composed of an alpha- chain subunit (69 kDa) and a beta-chain subunit (34 kDa), which are linked by a disulfide bond. The alpha-chain subunit contains an N-terminal hairpin domain and four kringle domains; the beta-chain subunit is a serine-protease-like domain lacking catalytic activity due to mutations in essential residues. The intracellular portion of c-Met, which is responsible for signal transduction, is composed of a juxtamembrane domain, a tyrosine kinase domain, and a C-terminal regulatory tail.
In the tyrosine kinase domain, two tyrosine residues (Tyr 1234 and Tyr 1235) regulate the kinase activity of c-Met. HGF/c-Met signaling activates multiple signal transduction pathways including the Src/focal adhesion kinase (FAK) pathway, the p120/signal transducer and activator of transcription (STAT) 3 pathway, the phosphoinositide- 3 kinase (PI3K)/Akt pathway, and the Ras/MEK pathway. Hepatocyte growth factor and its receptor (the product of the c-met protooncogene) are believed to be necessary for the normal growth and development of many tissues and organs. The expression of HGF and HGFR genes are unregulated in several types of human cancer; therefore, understanding the control mechanisms governing HGF and HGFR gene expression is of great clinical interest.
References
1.Weon-Kyoo You,et al. BMB Rep. 2008 Dec 31; 41(12): 833–839.
2.Dale P Corkery,et al. Nucleus. 2015; 6(4): 279–288.
In the tyrosine kinase domain, two tyrosine residues (Tyr 1234 and Tyr 1235) regulate the kinase activity of c-Met. HGF/c-Met signaling activates multiple signal transduction pathways including the Src/focal adhesion kinase (FAK) pathway, the p120/signal transducer and activator of transcription (STAT) 3 pathway, the phosphoinositide- 3 kinase (PI3K)/Akt pathway, and the Ras/MEK pathway. Hepatocyte growth factor and its receptor (the product of the c-met protooncogene) are believed to be necessary for the normal growth and development of many tissues and organs. The expression of HGF and HGFR genes are unregulated in several types of human cancer; therefore, understanding the control mechanisms governing HGF and HGFR gene expression is of great clinical interest.
References
1.Weon-Kyoo You,et al. BMB Rep. 2008 Dec 31; 41(12): 833–839.
2.Dale P Corkery,et al. Nucleus. 2015; 6(4): 279–288.
Angiogenesis
c-Met/HGFR
-
LMTK3-IN-1
产品货号 : M36996
cas no: 2764850-23-7
LMTK3-IN-1 (compound C28) 是狐猴酪氨酸激酶 3 (LMTK3) (Kd=2.5 μM) 的 ATP 竞争性抑制剂,通过泛素蛋白酶体途径降解 LMTK3 发挥作用。LMTK3-IN-1 在多种癌细胞系和体内 BC 小鼠模型中显示出抗癌活性。10-20 μM LMTK3-IN-1 可诱导 BC 细胞系凋亡。 -
Telisotuzumab
产品货号 : M36894
cas no: 1781223-80-0
Telisotuzumab (ABT-700) 是一种人源化重组二价抗体,针对肝细胞生长因子受体(MET)的治疗性抗体,可以高亲和力结合 c-Met 并抑制 c-Met 信号传导。Telisotuzumab 具有抗肿瘤活性。 -
Amivantamab
产品货号 : M36821
cas no: 2171511-58-1
Amivantamab (JNJ-61186372)?是一种人源 EGFR-MET 双特异性抗体,具有免疫抗癌活性。Amivantamab 可以抑制配体结合,促进受体-抗体复合物的内吞作用和降解,并诱导巨噬细胞的 Fc 依赖性胞吞作用和自然杀伤细胞的抗体依赖性细胞毒性。 -
Onartuzumab
产品货号 : M36715
cas no: 1133766-06-9
Onartuzumab (MetMAb) 是一种人源化亲和成熟的单价单克隆抗体,抑制受体酪氨酸激酶 MET。Onartuzumab 可有效抑制 HGF 结合、受体磷酸化和信号转导。Onartuzumab 具有抗体样药代动力学和抗肿瘤活性。 -
Rilotumumab
产品货号 : M36702
cas no: 872514-65-3
Rilotumumab (AMG 102) 是一种 anti-HGF (抗肝细胞生长因子) 的单克隆抗体,抑制 HGF/MET 驱动的信号传导。Rilotumumab 具有抗肿瘤活性,可用于去势抵抗性前列腺癌 (CRPC) 和实体瘤的研究。